文献速递膀胱癌与上尿路尿路上皮癌

基因组图谱可能成为上尿路尿路上皮癌的诊断和预后标志物

Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma.
PubMed 文献 · BJU Int · 2021-08-29

本研究对39例接受肾输尿管切除术的上尿路尿路上皮癌患者进行388基因panel二代测序,中位随访10.6年。肿瘤突变负荷与分期、分级显著相关,不同分级突变模式不同;死于UTUC的患者在TP53、HRAS等基因有致病突变,而Ta G1且FGFR3突变者无死于UTUC。基因组分析与组织病理学高度一致,并可提供预后信息。

要点

  • 肿瘤突变负荷与UTUC分期、分级显著相关
  • 不同分级肿瘤具有不同的突变模式
  • TP53、HRAS突变见于死于UTUC的患者,FGFR3突变Ta G1患者无死亡

核心结论

  • 基因组分析与组织病理学特征高度一致,并在部分病例中提供预后信息,可能有助于未来选择治疗和随访方案。

研究设计与样本

  • 回顾性队列研究,纳入2005至2012年接受肾输尿管切除术的39例UTUC患者,随访至2020年11月。
  • 从石蜡包埋肿瘤组织提取DNA,使用388基因panel进行二代测序。
  • 先以主成分分析和层次聚类盲法分析突变模式,再用方差分析比较不同分级、分期和生存组中富集的突变,并人工注释高分级/分期和/或生存差肿瘤中过表达的致病突变。

主要发现

  • 队列涵盖所有肿瘤分期和分级,中位随访10.6年,随访期间11例患者死于UTUC。
  • 肿瘤突变负荷与分期、分级及分期+分级均呈统计学显著相关。
  • Grade 1、Grade 2和Grade 3肿瘤具有不同的突变模式。
  • 死于UTUC的患者在特定基因(如TP53和HRAS)存在致病突变。
  • 已知致病FGFR3突变的Ta Grade 1肿瘤患者未死于UTUC。

临床怎么用

  • 基因组图谱结果与组织病理学特征高度一致,可辅助识别高危UTUC患者。
  • 对特定基因突变(如TP53、HRAS、FGFR3)的检测可能有助于预后分层,从而影响治疗和随访方案的选择。

局限性

  • 样本量较小(39例),结论需更大规模研究验证。
  • 研究为回顾性设计,基因组分析的临床效用尚需前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate gene alterations as diagnostic and prognostic markers in upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS: Patients with UTUC who underwent nephroureterectomy between 2005 and 2012 were followed until November 2020. DNA was extracted from paraffin-embedded tumour tissue. Next-generation sequencing using a 388-gene panel was performed. First a blinded analysis using principal component analysis and hierarchical clustering was used to search for patterns of mutations. Then a comparative analysis using analysis of variance (ANOVA) was used to search for mutations enriched in groups of various grades, stages, and survival. In addition, careful manual annotation was used to identify pathogenic mutations over-represented in tumours of high grade/stage and/or poor survival. RESULTS: A total of 39 patients were included. All tumour stages and grades were represented in the cohort. The median follow-up was 10.6 years. In all, 11 patients died from UTUC during the follow-up. Tumour mutational burden showed a statistically significant correlation with stage, grade, and stage + grade. Grade 1, Grade 2, and Grade 3 tumours had different mutational patterns. Patients who died from UTUC had pathogenic mutations in specific genes e.g. tumour protein p53 (TP53) and HRas proto-oncogene, GTPase (HRAS). Patients with Ta Grade 1 tumours with a known pathogenic fibroblast growth factor receptor 3 (FGFR3) mutation did not die from UTUC. CONCLUSION: The genetic analysis was highly concordant with histopathological features and added prognostic information in some cases. Thus, results from genomic profiling may contribute to the choice of treatment and follow-up regimens in the future.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Grahn A, Eisfeldt J, Malm C, et al. Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma. BJU Int. 2021. PMID: 34375486. doi:10.1111/bju.15566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。